Palatin Technologies, Inc.

Equities

PTN

US6960775020

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
1.84 ^USD	-2.65%		-4.17%	-53.77%

Apr. 08	Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	CI
Feb. 28	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Palatin Technologies, Inc Announces Extension of Agreement with Lonza Ltd

November 30, 2022 at 04:16 pm EST

The agreement of Palatin Technologies, Inc. with Lonza Ltd. to manufacturer the VyleesiÂ® active drug ingredient was set to expire December 31, 2022. The Company engaged in discussions with Lonza and, on November 23, 2022, the Company and Lonza agreed to extend the term of the Lonza Agreement until June 30, 2024.

Latest news about Palatin Technologies, Inc.

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024	Apr. 08	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Feb. 28	MT
Palatin Shares Skid After Dry Eye Drug Candidate Misses Part of Targets in Late-Stage Trial	Feb. 28	MT
Transcript : Palatin Technologies, Inc. - Special Call	Feb. 28
Transcript : Palatin Technologies, Inc., Q2 2024 Operating Results Call, Feb 15, 2024	Feb. 15
Palatin Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease	Feb. 05	CI
Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024	Jan. 08	CI
Cosette Pharmaceuticals, Inc. acquired worldwide rights to Vyleesi from Palatin Technologies, Inc. for approximately $170 million.	Dec. 19	CI
Top Premarket Decliners	Dec. 15	MT
Transcript : Palatin Technologies, Inc., Q1 2024 Earnings Call, Nov 14, 2023	Nov. 14
Palatin Technologies, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
Palatin Technologies, Inc. announced that it has received $5.000001 million in funding	23-10-23	CI
Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding	23-10-22	CI
Palatin Technologies Says Preclinical Data for Weight-Loss Therapy Showed Body Weight Loss of Up to 5.1%	23-10-18	MT
Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients	23-10-18	CI
Palatin Technologies Gets Non-Compliance Notice From NYSE American	23-10-13	MT
Transcript : Palatin Technologies, Inc., Q4 2023 Earnings Call, Sep 28, 2023	23-09-28
Earnings Flash (PTN) PALATIN TECHNOLOGIES Posts Q4 Revenue $1.8M, vs. Street Est of $1.4M	23-09-28	MT
Palatin Technologies, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2023	23-09-28	CI
North American Morning Briefing : Rising Oil -2-	23-09-28	DJ
North American Morning Briefing : The Post-Fed Selloff Continues	23-09-21	DJ
Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease	23-09-07	CI
Palatin Technologies Launches Clinical Program Evaluating Combination of Bremelanotide, PDE5i to Treat Erectile Dysfunction	23-08-10	MT
Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment	23-08-10	CI

Chart Palatin Technologies, Inc.

Duration

Period

More charts

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with unmet medical need and commercial potential. Its new product development activities focus primarily on MC1r agonists, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also engaged developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. It has completed Phase III PL9643 clinical study for dry eye disease. It is also conducting Phase II study of oral PL8177 in patients with ulcerative colitis.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Palatin Technologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.84 USD

Average target price

9.333 USD

Spread / Average Target

+407.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PALATIN TECHNOLOGIES, INC.	-53.77%	30.5M
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs